Although PRX4’s role is not fully understood, our findings and those of other studies suggest that PRX4 may act as a potential prognostic biomarker and therapeutic target in CRC, reflecting its complex role in tumor progression. This evidence concerns the gene PRDX4 and colorectal carcinoma.